Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ELYM

ELYM - Eliem Therapeutics, Inc. Stock Price, Fair Value and News

$3.02+0.11 (+3.78%)
Market Closed

Price Targets

ELYM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ELYM Price Action

ELYM RSI Chart

ELYM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ELYM Valuation

Market Cap

144.3M

Price/Earnings (Trailing)

-2.41

Price/Sales (Trailing)

17.74

Price/Free Cashflow

-2.64

ELYM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ELYM Fundamentals

ELYM Revenue

Revenue (TTM)

8.1M

ELYM Earnings

Earnings (TTM)

-59.9M

Earnings Growth (Yr)

-108.13%

Earnings Growth (Qtr)

-35.91%

ELYM Profitability

Return on Equity

-37.3%

Return on Assets

-35.68%

Free Cashflow Yield

-37.81%

ELYM Investor Care

Shares Dilution (1Y)

1.43%

Diluted EPS (TTM)

-0.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20245.1M008.1M
20232.2M3.0M3.8M4.6M
20220001.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Eliem Therapeutics, Inc.

ELYM
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
 WEBSITEhttps://eliemtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES30

Eliem Therapeutics, Inc. Frequently Asked Questions

ELYM is the stock ticker symbol of Eliem Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Sat Feb 28 2026, market cap of Eliem Therapeutics, Inc. is 144.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Sat Feb 28 2026, ELYM's PE ratio (Price to Earnings) is -2.41 and Price to Sales (PS) ratio is 17.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELYM PE ratio will change depending on the future growth rate expectations of investors.